Blod Biomarkers for Stroke
Blood Biomarkers of Metabolic Processes (Metabolomics) and Brain Derived Proteins in Stroke Patients.
調査の概要
状態
条件
詳細な説明
Approximately 12,000 Danes suffer a stroke each year with major consequences for those affected, their relatives and society in general. Rapid diagnosis and treatment mean less brain damage and thus less risk of late sequelae. A marker in the blood that is specific for stroke could result in faster diagnose and thereby treatment. Until now, no such marker has been found, but measurement of the so-called metabolomics and different fragments of brain proteins like Tau has shown promising results. Currently, metabolomics has only been studied in two other projects in stroke patients, and the results were not complete and a subtype of Tau (Tau-C) has been shown to be related to brain damage after ice hockey, but this is not studied in stroke patients, so there is a need for more studies.
In this project different fragments of brain proteins and the so-called metabolomics in the blood, which are small residues from the biological processes that take place in the body, such as fat and sugar incineration, will be studied.
The project is based on blood samples from a biobank that has been established in connection with previous projects in the Stroke Unit, Neurological Clinic, Rigshospitalet, Glostrup. All subjects have given written consent to give blood for future research.
Fifty microliters of blood from each participant will be analyzed by so-called mass spectroscopy, a well-researched method and performed in a recognized laboratory using known libraries and databases of metabolites for the determination and ongoing quality control. In addition, 250 microliters of serum will be analyzed by Elisa to detect brain proteins like Tau and Brevican.
The metabolomic profile and the brain proteins is compared to the information we have about the participants, namely:
- If they had ischemic or hemorrhagic stroke or if it is a healthy control person
- The extent of brain damage; partly measured by the brain scan and partly from the patient's symptoms
- The cause of the stroke
研究の種類
入学 (予想される)
連絡先と場所
研究場所
-
-
-
Glostrup、デンマーク、2600
- Department of clinical stroke research, department of neurology, Glostrup Hospital
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Clinical stroke
Exclusion Criteria:
- Glasgow Coma Scale (GCS) < 15
- Non communicating patients e.g. aphasia (incompetent patients)
- Unable to cooperate to the physical examinations
- Pregnancy or nursing mothers
- If the investigators find the study participant unfit to conduct the investigations
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:コホート
- 時間の展望:断面図
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
Ischemic or hemorrhagic stroke
時間枠:Within 7 days
|
We hope to find a method to differentiate between ischemic and hemorrhagic stroke.
|
Within 7 days
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
---|---|---|
The extend of the brain damage
時間枠:Within 7 days
|
The relation between the biomarkers and brain damage measured by MRI.
|
Within 7 days
|
The extend of the physical damage
時間枠:Within 7 days
|
The relation between the biomarkers and brain damage measured by NIHSS.
|
Within 7 days
|
Etiology of stroke
時間枠:Within 7 days
|
The relation between the biomarkers and stroke etiology measured by the TOAST criteria.
|
Within 7 days
|
Stroke patient or healthy subject
時間枠:Within 7 days
|
The relation between the biomarkers and healthy subjects.
|
Within 7 days
|
協力者と研究者
捜査官
- 主任研究者:Helle K Iversen, MD, DMSc、Department of clinical stroke research, Neurological department, Rigshospitalet, Glostrup
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (予想される)
研究の完了 (予想される)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。